Renalytix AI PLC (RNLX)
| Market Cap | 1.06B |
| Revenue (ttm) | 400,000 |
| Net Income (ttm) | n/a |
| Shares Out | 36.02M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 11 |
| Last Price | $27.61 |
| Previous Close | $28.99 |
| Change ($) | -1.38 |
| Change (%) | -4.76% |
| Day's Open | 28.21 |
| Day's Range | 27.28 - 28.73 |
| Day's Volume | 65,608 |
| 52-Week Range | 9.91 - 33.00 |
NEW YORK, May 4, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX) (NASDAQ: RNLX), announced today that COVID-SeroKlir, its...
Renalytix AI plc (NASDAQ: RNLX) stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services. Th...
Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021 Data from 1,325 CANVAS Participants with...
Agreement provides RenalytixAI with exclusive option to access intellectual property surrounding a comprehensive panel of novel biomarkers in kidney disease Agreement provides RenalytixAI with exclusive...
Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings Value of KidneyIntelX Testing Demonstrated by Data from ...
Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes Clinical findings published in the April issue of Diabetologia,...
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of ki...
Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatment of chron...
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), the artificial intelligence-enabled in vitro diagnostics company, focused on opt...
Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease ...
Renalytix AI (RNLX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs First-of-...
NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kid...
NEW YORK, Dec. 2, 2020 /PRNewswire/ --The National Kidney Foundation (NKF) announced today a partnership with Renalytix AI (NASDAQ:RNLX) to improve kidney disease diagnosis and assessment in the earlies...
AIM ImmunoTech (NYSE: AIM) shares are trading higher on Wednesday after the company dosed its first patient in a study evaluating ampligen as part of combination treatment for patients with cancer and C...
About RNLX
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed produc... [Read more...]
| Industry Diagnostics & Research | IPO Date Jul 17, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol RNLX |